Invasive lobular carcinoma of the breast: Role of endothelial lymphatic marker D2-40

Annals of Clinical and Laboratory Science

Volumn 38, Issue 2, 2008, Pages 99-104

  Laser, Jordan ^a   Cangiarella, Joan ^a   Singh, Baljit ^a   Melamed, Jonathan ^a   Chiriboga, Luis ^a   Yee, Herman ^a   Darvishian, Farbod ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; D2 40 antibody; Lymphovascular invasion; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY D2-40; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, LOBULAR; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 43449136479     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:149-156.
2. Ferlicot S, Vincent-Salomon A, Médioni J, Genin P, Rosty C, Sigal-Zafrani B, Fréneaux P, Jouve M, Thiery JP, Sastre-Garau X. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004;40:336-341.
3. Mersin H, Yildirim E, Gulben K, Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 2003;29:390-395.
4. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ. Infiltrating lobular carcinoma-a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004;13:389-396.
5. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996;77:113-120.
6. Grube BJ, Hansen NM, Ye X, Giuliano AE. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 2002;184:372-376.
7. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-957.
8. Chen M, Palleschi S, Khoynezhad A, Gecelter G, Marini CP, Simms HH. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137:606-609.
9. Weiser MR, Montgomery LL, Tan LK, Susnik B, Leung DY, Borgen PI, Cody HS 3rd. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 2001;8:145-149.
10. Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, Olivotto IA. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg 2005;200:912-921.
11. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, De Placido S. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995;76:1772-1778.
12. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blarney RW, Elston CW Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-47.
13. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R. Austrian Breast and Colorectal Cancer Study Group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-312.
14. Nime FA, Rosen PP, Thaler HT, Ashikari R, Urban JA. Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1977;1:25-30.
15. Les AK, DeLellis RA, Silverman ML, Wolfe HJ. Lymphatic and blood vessel invasion in breast carcinoma: a useful prognostic indicator? Hum Pathol 1986;17:984-987.
16. Chua B, Ung O, Taylor R, Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001;71:723-728.
17. Roses DF, Bell DA, Flotte TJ, Taylor R, Ratech H, Dabin N. Pathologic predictors of recurrence in stage 1 (TIN0M0) breast cancer. Am J Clin Pathol 1982;78:817-820.
18. McCready DR, Chapman JA, Hanna WM, Kahn HJ, Yap K, Fish EB, Lickley HL. Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients. Ann Surg Oncol 2000;7:562-567.
19. Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990;8:1457-1465.
20. Bailey D, Marks A, Stratis M, Baumal R. Immunohistochemical staining of germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody. Mod Pathol 1991;4:167-171.
21. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
22. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M. D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol 2006;19:974-985.
23. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
24. Bailey D, Baumal R, Law J, Sheldon K, Kannampuzha P, Stratis M, Kahn H, Marks A. Production of a monoclonal antibody specific for seminomas and dysgerminomas. PNAS USA 1986;83:5291-5295.
25. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 2007;20:183-191
26. Page DL, Anderson, TJ. Miscellaneous features of carcinoma. In: Diagnostic Histopathology of the Breast, 4th ed, Langman Group, London, 1987; pp 283-284.
27. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging System. 6th ed, Springer, New York, 2002.
28. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999;230:692-696.
29. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
30. Bentz JS, Yassa N, Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 1998;11:814-822.
31. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23:655-662.
32. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992;23:1167-1171.
33. Hoda SA, Hoda RS, Merlin S, Shamonki J, Rivera M. Issues relating to lymphovascular invasion in breast carcinoma. Adv Anat Pathol 2006;13:308-315.
34. Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu 1983;18:215-232.
35. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ. St Gallen Expert Panel Members. First select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006;17:1772-1776.
36. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006;94:1643-1649.